Physician profile
Thomas T Chen
NPI 1164415899
$9,925.32
in general payments reported to CMS, 2019-2025
29 companies · $1,790 in 2025
The $1,790 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,539 · 2020: $992 · 2021: $1,338 · 2022: $1,154 · 2023: $1,355 · 2024: $1,758 · 2025: $1,790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,744 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,743.71 |
| Education | $158.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $1,770.07 | 2019-2025 | Acticor 7 Vr-T Dx, Amvia Edge, Biomonitor |
| Janssen Pharmaceuticals, INC | $1,200.13 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,145.30 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,133.76 | 2021-2025 | Verquvo, Capvaxive, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $833.94 | 2019-2025 | Jardiance |
| Amgen INC. | $678.17 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $563.05 | 2019-2025 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $373.20 | 2024-2025 | Opsumit, Uptravi |
| Pfizer INC. | $277.25 | 2019-2024 | |
| Amarin Pharma, INC. | $256.32 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $222.15 | 2019-2025 | Eliquis, Camzyos |
| Edwards Lifesciences Corporation | $179.15 | 2020-2025 | Sapien 3 Ultra Resilia |
| Biohaven Pharmaceutical Holding Company Ltd. | $168.83 | 2022 | |
| Abbott Laboratories | $166.53 | 2020-2023 | Aveir, Mitraclip |
| Scpharmaceuticals INC. | $154.80 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $109.25 | 2022-2023 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $106.81 | 2021-2025 | |
| Gilead Sciences, INC. | $101.71 | 2019 | |
| Esperion Therapeutics, INC. | $92.00 | 2020-2025 | Nexletol |
| Heartflow, INC. | $87.53 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $57.26 | 2019-2021 | |
| Angiodynamics, INC. | $54.26 | 2019-2020 | |
| Boston Scientific Corporation | $45.82 | 2021-2024 | Watchman Flx |
| Lexicon Pharmaceuticals, INC. | $39.89 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $24.26 | 2019 | |
| Solventum Corporation | $23.43 | 2025 | Prevena, V.A.C.Ulta |
| Allergan, INC. | $22.73 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $22.72 | 2019 | |
| Bardy Diagnostics, INC. | $15.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.